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in the Azi group (12%, 26 of 224) compared to the Clari
group (6%, 14 of 221). The total drug costs for additional
antibiotics were $853 and $690 for the Azi and Clari
groups, respectively. The major reason for additional anti-
biotics was due to bacteriological and clinical failures.
CONCLUSIONS: Clari is superior to Azi in the eradica-
tion of S. pyogenes and in the resolution of symptoms of
pharyngitis/tonsillitis. In addition, more subjects in the
Azi group had additional antibiotics prescribed for phar-
yngitis/tonsillitis during the follow-up period. The lower
rate of additional antibiotic usage would be expected to
result in cost savings in the overall management of phar-
yngitis/tonsillitis.
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OBJECTIVE: To supplement previous efficacy analyses
from pivotal Phase III trials with a comparison of the
community-acquired pneumonia (CAP)-related costs of
inpatient treatment using either IV levofloxacin or IV
ceftriaxone as initial primary therapy.
METHODS: Patients with a primary diagnosis of CAP
were enrolled in a prospective, randomized, open-label, ac-
tive-controlled Phase III clinical trial. They were assigned
to one of two treatment groups: levofloxacin (IV or PO)
and ceftriaxone (IV) and/or cefuroxime axetil (PO) in in-
patient and outpatient settings. Resource utilization data
were collected alongside clinical trial data. To make legiti-
mate and meaningful cost comparisons between similar
types of patients (inpatients) getting similar (IV) drugs, this
economic analysis examined only the resource utilization
of inpatient trial enrollees who received IV formulations as
initial treatment. Medicare resource cost estimates were
multiplied by resource units used by patients to generate
cost estimates. Sample size had been determined based on
efficacy endpoints in the Phase III trial protocol.
RESULTS: The results showed a statistically significant
total cost difference per patient that favored levofloxacin
over ceftriaxone ($6012 versus $7422; a difference of
$1410; p  0.048). Levofloxacin was also associated
with a statistically significant reduction in mean study
medication cost per patient ($195 versus $388; a differ-
ence of $193; p  0.0001).
CONCLUSIONS: As initial primary inpatient treatment
of adults with community-acquired pneumonia, IV levof-
loxacin is less costly than IV ceftriaxone, the most pre-
scribed inpatient CAP treatment.
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OBJECTIVES: The study purpose was to determine
whether a disease management program (DSM) using
dyspepsia guidelines would improve provider compliance
with “best practices” and result in improved health and/
or economic outcomes.
METHODS: We randomized eight clinics in a capitated
managed care medical group to “usual care” versus a dys-
pepsia DSM for non-NSAID and NSAID-related dyspep-
sia. This analysis includes only patients with non-NSAID-
related dyspepsia. The program included the use of evi-
dence-based practice guidelines, “on-site” HP testing, aca-
demic detailing of physicians, and patient education.
Symptom severity, and quality of life were measured at
baseline, 3 and 6 months, and compliance with guidelines
and utilization was assessed at 6 months.
RESULTS: One hundred sixty-seven intervention and 180
control patients entered the final analysis. There were no
significant differences in baseline characteristics in the two
groups. HP testing was performed in 61% of intervention
and 11% of control patients (P  0.001). Appropriate
anti-HP therapy was given to 100% of HP-positive inter-
vention patients and 0% of HP-positive control patients
(P  0.001). Drug costs were reduced by $4.70 PMPM in
the intervention group compared to the control group (P 
0.001). Other than a reduction in costs attributable to
barium radiography in the intervention group (P  0.05),
there were no significant differences between groups in
the costs attributable to non-drug resource utilization.
Symptom severity and quality of life scores were similar
between groups at 3 and 6 months.
CONCLUSIONS: This preliminary analysis suggests that
a DSM using evidence-based guidelines and academic de-
tailing improved the process of care for patients with dys-
pepsia not taking NSAIDs. Implementation of this DSM
resulted in significant reductions in PMPM pharmacy
costs, without compromising symptom severity or health-
related quality of life.
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OBJECTIVE: To compare the impact of a disease man-
agement program to routine care on quality and costs of
care in diabetic patients.
METHODS: A pre-/post-analysis was performed to eval-
uate a comprehensive multidisciplinary diabetes disease
management (DM) program implemented in a multispe-
cialty medical group. Eighty-two adults with diabetes
(Type I or II) and elevated glycohemoglobin levels were
co-managed by a nurse practitioner and an endocrinolo-
gist in a diabetes DM clinic. Evidence-based guidelines
were utilized to assist care. Only patients enrolled with
the medical group for one year prior to the intervention
were deemed eligible for analysis. Quality of care was
evaluated by comparing glycosylated hemoglobin values
and the documented performance of preventive measures
in the year prior to and following the intervention. Dif-
ferences in visit costs are reported.
RESULTS: Glycohemoglobin levels changed by 0.8% in
the pre-intervention period and 	2.43% in the post-inter-
vention period (p  0.01). Statistically significant (p 
0.01) increases in rates of documented preventive measures
were noted as follows: foot exam (74% versus 99%); diet
counseling (49% versus 100%); blood pressure screening
(86% versus 100%); and exercise counseling (21% versus
100%). Changes in rates of influenza vaccination (30%
versus 41%); retinal examination (59% versus 68%); and
cholesterol screening (77% versus 74%) were not statisti-
cally significant. Visit costs increased from $211 per patient
in the pre-intervention period to $409 per patient in the
post-intervention period (p  0.01).
CONCLUSIONS: Implementation of a comprehensive
DM program for diabetic patients resulted in significant
reductions in glycohemoglobin levels and significant im-
provements in some, but not all, preventive care mea-
sures. Outpatient visit costs increased significantly as a
result of this intervention.
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National Cholesterol Education Program (NCEP) guide-
lines establish target levels for low density lipoprotein
(LDL) based on risk factors for coronary heart disease
(CHD). Achieving these goals in clinical practice is chal-
lenging, but has been shown to significantly reduce cardio-
vascular morbidity and mortality.
OBJECTIVE: This study was conducted to measure im-
provements in cholesterol control through implementa-
tion of national guidelines, utilizing a multidisciplinary
approach to hyperlipidemia disease management.
METHODS: A pre-/post-design was used to analyze the ef-
fectiveness of a pharmacist-run hyperlipidemia disease
management clinic in a staff-model medical group, enroll-
ing both managed care and fee-for-service patients (n 
203) with LDL levels exceeding NCEP goals. Patients were
identified from administrative data and primary care physi-
cian (PCP) referral. LDL goals were established in accor-
dance with NCEP guidelines. Patients were divided into
primary and secondary CHD prevention groups. Evidence-
based treatment guidelines were used to direct care, with
dietician and PCP consults at the pharmacists’ discretion.
RESULTS: By intention-to-treat analysis both primary
and secondary prevention groups had statistically signifi-
cant improvements in total cholesterol (	28 mg/dL and
	33 mg/dL, respectively, p  0.01), LDL (	26 mg/dL
and 	31 mg/dL, respectively, p  0.01), triglycerides
(	22 mg/dL and 	47 mg/dL, respectively, p  0.01) and
high density lipoprotein (3.3 mg/dL and 4.2 mg/dL,
respectively, p  0.01). Fifty-one percent of patients
reached their NCEP defined LDL goal. There was no sig-
nificant difference in percentage of patients achieving
goal LDL levels among the different treatment groups.
Medication costs increased for the secondary prevention
group ($9.32, p  0.01), decreased slightly for the pri-
mary prevention group (	$0.66, p  NS).
CONCLUSIONS: A multidisciplinary approach to hy-
perlipidemia disease management can provide significant
improvements in cholesterol control.
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The number of elderly Americans has increased dramati-
cally in recent years, and this trend will continue. It is criti-
cal to identify cost-effective interventions to promote the
general health of elderly people.
OBJECTIVE: To evaluate the cost-effectiveness of pre-
ventive occupational therapy on healthy elderly people.
METHODS: One hundred sixty-three individuals from
government subsidized senior apartments were random-
ized into three experimental conditions: individuals in the
occupational therapy group received 2 hours per week of
group-based intervention and 1 hour per month of indi-
vidual-based intervention; individuals in the social group
engaged in social activities, such as dancing, watching
movies, and community outings; and participants in the
control group remained untreated. The trial period con-
sisted of a 9-month treatment phase and a 6-month follow-
up phase. Monthly telephone interviews were conducted
to collect information on patients’ healthcare utilization.
In addition, all participants were evaluated at pre-test,
post-test, and follow-up stages by using the SF-36 ques-
tionnaire. The Current Procedural Terminology and the
Diagnosis Related Group databases were used to convert
the utilization information into costs. A prediction model
was used to compute each patient’s quality of well-being
index by using the SF-36 domain scores.
